Menopause marks the permanent cessation of menstruation, typically occurring between ages 45 and 55. The menopausal transition, or perimenopause, lasts 4–10 years, characterised by fluctuating hormones, irregular cycles, and variable symptoms. Treatment aims to manage vasomotor, mood, and metabolic changes whilst reducing long-term health risks.
Diagnosis is clinical, confirmed by elevated FSH levels and absent menstruation for 12 months. Hormone replacement therapy (HRT) remains the gold standard, providing the fastest symptom relief and the strongest evidence for bone and cardiovascular protection. HRT regimens combine oestrogen (transdermal patches, oral tablets, vaginal creams) with progestogen (oral tablets, intrauterine devices, or patches) and are individualised by symptom severity, personal health history, and tolerability. Non-hormonal pharmacotherapy includes selective serotonin reuptake inhibitors (SSRIs: sertraline, paroxetine) and serotonin–noradrenaline reuptake inhibitors (SNRIs: venlafaxine, desvenlafaxine) for vasomotor symptoms; these are particularly useful in women with contraindications to HRT or breast cancer history. Gabapentin, a neuroleptic agent, and clonidine offer alternative pharmacological options. Lifestyle modifications—regular aerobic and resistance exercise, adequate sleep, stress management, and dietary calcium—are foundational.
Phytoestrogenic herbs including black cohosh, red clover, sage leaf, and dong quai are widely used; clinical evidence shows variable symptom relief, typically modest (20–30% improvement above placebo in some trials). Acupuncture is explored for hot flushes and mood; some studies report meaningful symptom reduction, though effect sizes remain small. Homeopathy and Traditional Chinese Medicine (TCM) herbal formulas are practised but lack robust clinical validation. Dietary modifications emphasising soy-based foods, flax seeds, and phytonutrient density reflect traditional support; micronutrient supplementation including magnesium and B vitamins may improve overall wellbeing.
Stem cell approaches are studied for menopause, primarily investigating ovarian regeneration to restore physiological oestrogen production and delay or reverse menopausal transition. Bone marrow-derived and adipose tissue stem cells are evaluated in preclinical work; proposed mechanisms target granulosa cell renewal and follicle reserve restoration. Early pilot studies in some centres report improvements in oestrogen markers and menstrual regularity, but evidence is highly preliminary and outcomes are not standardised. Candidate assessment focuses on women with severe vasomotor or metabolic complications unsuitable for conventional HRT.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Hormone replacement therapy (HRT) | Standard | Strong | €60–€180/month | Low | Ongoing |
| SSRI/SNRI antidepressants | Standard | Strong | €20–€80/month | Low | 4–8 weeks |
| Gabapentin | Standard | Moderate | €30–€100/month | Low | 2–4 weeks |
| Black cohosh & herbal supplements | Alternative | Limited | €20–€60/month | Low | Ongoing |
| Acupuncture | Alternative | Moderate | €60–€120 per session | Low | Immediate |
| Ovarian stem cell regeneration | Regenerative | Investigational | €20,000–€40,000 | Medium | 6–8 weeks |
| Lifestyle: exercise & dietary optimisation | Standard | Strong | €0–€200/month | Low | Ongoing |
Most women experience significant improvement within 2–4 weeks of HRT initiation; maximum benefit often appears by 3 months. Dosing adjustments may enhance response if initial relief is incomplete.
Current evidence supports physiological-dose HRT for symptom relief and bone health with acceptable safety in appropriate candidates. Individual risk—personal breast cancer history, thrombotic tendency, or cardiovascular disease—determines suitability and duration. Regular reassessment is recommended.
Perimenopause typically lasts 4–10 years, with an average of 7 years. The final menstrual period marks menopause; 12 months without menstruation confirms diagnosis. Post-menopausal status persists permanently.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם